PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,885 | -17.9% | 2,669 | +7.2% | 0.00% | -20.0% |
| Q2 2023 | $99,734 | +1.6% | 2,489 | +3.5% | 0.01% | 0.0% |
| Q1 2023 | $98,148 | -8.5% | 2,405 | -13.4% | 0.01% | 0.0% |
| Q4 2022 | $107,259 | -24.8% | 2,778 | +3.6% | 0.01% | -28.6% |
| Q3 2022 | $142,602 | -8.8% | 2,681 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $156,302 | -23.6% | 2,681 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $204,614 | -71.4% | 2,681 | -77.5% | 0.01% | -30.0% |
| Q4 2021 | $716,384 | +7.4% | 11,906 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $666,736 | -7.7% | 11,906 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $722,456 | -7.3% | 11,906 | +7.1% | 0.01% | -16.7% |
| Q1 2021 | $779,191 | +2.7% | 11,117 | -12.3% | 0.01% | +9.1% |
| Q4 2020 | $758,652 | -0.5% | 12,678 | 0.0% | 0.01% | -15.4% |
| Q3 2020 | $762,201 | +14.6% | 12,678 | 0.0% | 0.01% | +8.3% |
| Q2 2020 | $665,215 | +53.3% | 12,678 | -2.0% | 0.01% | +33.3% |
| Q1 2020 | $433,945 | -26.0% | 12,942 | 0.0% | 0.01% | -10.0% |
| Q4 2019 | $586,273 | +15.4% | 12,942 | -3.0% | 0.01% | +11.1% |
| Q3 2019 | $508,120 | -12.5% | 13,347 | 0.0% | 0.01% | -10.0% |
| Q2 2019 | $580,461 | +14.3% | 13,347 | 0.0% | 0.01% | +11.1% |
| Q1 2019 | $507,987 | -11.5% | 13,347 | 0.0% | 0.01% | -18.2% |
| Q4 2018 | $574,188 | -9.9% | 13,347 | +2.9% | 0.01% | 0.0% |
| Q3 2018 | $637,574 | -99.8% | 12,972 | 0.0% | 0.01% | +57.1% |
| Q2 2018 | $415,753,000 | +2.9% | 12,972 | 0.0% | 0.01% | +16.7% |
| Q1 2018 | $404,078,000 | +68156.4% | 12,972 | 0.0% | 0.01% | -25.0% |
| Q4 2017 | $592,000 | -40.9% | 12,972 | -51.4% | 0.01% | +33.3% |
| Q3 2017 | $1,002,000 | -21.3% | 26,681 | 0.0% | 0.01% | -33.3% |
| Q2 2017 | $1,273,000 | +12.2% | 26,681 | +7.2% | 0.01% | +12.5% |
| Q1 2017 | $1,135,000 | +35.9% | 24,885 | -3.8% | 0.01% | +33.3% |
| Q4 2016 | $835,000 | -5.6% | 25,861 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $885,000 | +1.5% | 25,861 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $872,000 | -36.4% | 25,861 | 0.0% | 0.01% | -45.5% |
| Q1 2016 | $1,370,000 | -30.5% | 25,861 | +0.8% | 0.01% | -26.7% |
| Q4 2015 | $1,970,000 | +85.5% | 25,654 | -0.7% | 0.02% | +87.5% |
| Q3 2015 | $1,062,000 | -42.5% | 25,838 | -1.0% | 0.01% | -38.5% |
| Q2 2015 | $1,846,000 | -24.1% | 26,098 | -4.7% | 0.01% | -27.8% |
| Q1 2015 | $2,433,000 | +0.1% | 27,381 | -0.1% | 0.02% | +5.9% |
| Q4 2014 | $2,431,000 | -8.5% | 27,421 | 0.0% | 0.02% | -10.5% |
| Q3 2014 | $2,658,000 | +5.5% | 27,421 | 0.0% | 0.02% | +11.8% |
| Q2 2014 | $2,519,000 | +61.3% | 27,421 | +22.9% | 0.02% | +54.5% |
| Q1 2014 | $1,562,000 | +21.7% | 22,314 | 0.0% | 0.01% | +22.2% |
| Q4 2013 | $1,283,000 | +19.6% | 22,314 | 0.0% | 0.01% | +12.5% |
| Q3 2013 | $1,073,000 | +65.8% | 22,314 | 0.0% | 0.01% | +60.0% |
| Q2 2013 | $647,000 | – | 22,314 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |